Federal Court Holds Manufacturer of Investigational Drug and Medical Device Responsible for Clinical Trial Investigator’s Allegedly Inadequate Informed Consent Form

by Foley Hoag LLP

In a recent decision subject to multiple flaws, the United States District Court for the District of Massachusetts refused to dismiss a suit against the manufacturer of an investigational drug and medical device used in a clinical trial based on the allegedly inadequate warnings the clinical trial investigator provided to patients in obtaining their informed consent to the trial. If left unchanged, the decision could be applicable even outside the clinical trial context if it is alleged that a pharmaceutical or device manufacturer had knowledge of a physician’s warnings to his or her patients.

Plaintiff in Zeman v. Williams, 2014 U.S. Dist. LEXIS 91501 (D. Mass. July 7, 2014), participated in a clinical trial designed to investigate the treatment of Young-Onset Parkinson's Disease by delivering an investigational gene therapy agent through an investigational brain infusion delivery system. Although the study protocol required the gene therapy to be delivered to both sides of plaintiff’s brain, the clinical trial investigator allegedly erroneously delivered it only to one side, thereby causing serious harm. Plaintiff filed suit against multiple defendants, including the investigator for medical malpractice and failure to obtain an adequate informed consent to the clinical trial, asserting that the consent form he gave plaintiff failed to warn, among other things, of the possibility and risks of improper placement of the therapeutic agent and that the therapy was experimental. Plaintiff also sued the alleged manufacturer of both the gene therapy agent and brain delivery system, alleging it participated in drafting and approving the consent form.

The manufacturer moved to dismiss, arguing it owed no duty to plaintiff regarding the consent form, but the court denied the motion. The court acknowledged that under federal regulations it was the clinical trial investigator’s duty actually to obtain the patient’s informed consent, but the defendant manufacturer, as the clinical trial sponsor, was responsible both for selecting qualified investigators and “providing them with the information they need to conduct the investigation properly.” Moreover, under the “learned intermediary” doctrine normally applicable to pharmaceutical product liability claims, a pharmaceutical manufacturer has a duty to give an adequate warning to the prescribing physician. Accordingly, the court held, notwithstanding the lack of any Massachusetts appellate authority imposing liability on a clinical trial sponsor for warnings given to trial subjects, the sponsor may be liable in tort “[i]f the investigator fails to inform a subject about some substantial risk because the sponsor has failed adequately to inform the investigator about the risk.” The court concluded plaintiff’s complaint specified the information lacking from the consent form sufficiently to state a claim.

Unfortunately, the court’s decision appears flawed in several respects. For one thing, the United States Court of Appeals for the First Circuit has repeatedly made clear that district courts within the circuit are not to “blaze new trails” in state law by recognizing liability theories that the state appellate courts have not. While the Massachusetts courts have recognized a physician’s duty to obtain an informed consent to treatment from the patient as an essential precondition to touching or otherwise invading the patient’s body, they have never recognized such a duty in third parties, such as manufacturers of prescription drugs or medical devices, who do not treat the patient. Moreover, the duties that are imposed on such manufacturers under product liability law normally arise because the manufacturer is a seller or lessor of its product, while the clinical trial sponsor here provided its products without charge in order to investigate their safety and efficacy, and under the learned intermediary rule any informational duty is normally limited to warning the treating physician, not to supervising her warnings to the patient.

Most centrally, however, while the court purported to recognize a possible claim based on the sponsor’s warnings to the investigator, it actually permitted the claim to proceed based solely on the contents of the consent form provided by the investigator to the patient, as the complaint contained no allegations whatsoever regarding what the sponsor allegedly failed to tell the investigator, much less that he did not otherwise know that information. Indeed, the information plaintiff complained was omitted from the consent form either would have been obvious to any reasonable investigator (that he could perform the procedure erroneously, with harmful consequences), or was in fact given (the consent form, attached to the complaint, described both “human gene transfer” generally, and “[t]he study agent” specifically, as “experimental”).

Finally, the decision’s rationale could be expanded to contexts involving already marketed, as opposed to purely investigational, drugs and medical devices. For example, if a plaintiff were to allege that her prescribing physician gave her written information about a drug or device, and that the manufacturer had a role in authoring the information, or even was aware of its content, the court’s rationale could hold the manufacturer liable for any failings in the information that the physician determined to provide.

Because the Zeman opinion is subject to the flaws noted above, we hope it will be corrected later in the litigation. In the meantime, however, pharmaceutical and device manufacturers should continue to exercise care when they are asked to review physicians’ patient consent forms or other informational literature, and to make clear that they are relying on the clinician to secure an adequate informed consent from the patient. In addition, manufacturers who confront claims in litigation similar to those advanced by the plaintiff in Zeman should be sure that their counsel vigorously resist any further propagation of that court’s errors.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley Hoag LLP | Attorney Advertising

Written by:

Foley Hoag LLP

Foley Hoag LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.